Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bionano Genomics Inc (NQ: BNGO )

1.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 144
Open 1.380
Bid (Size) 1.380 (10)
Ask (Size) 1.450 (2)
Prev. Close 1.380
Today's Range 1.380 - 1.380
52wk Range 1.160 - 7.460
Shares Outstanding 279,140,015
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Stocks That Could Double in 2022
With the market shaking off its downturn and the economy strengthening, there are several stocks that could double before the year is out. 
Via InvestorPlace
Looking Into Bionano Genomics's Return On Capital Employed
Bionano Genomics (NASDAQ:BNGO) brought in sales totaling $5.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 30.52%, resulting in a loss of $29.95 million. 
Via Benzinga

Performance

YTD
-57.28%
-57.28%
1 Month
-20.23%
-20.23%
3 Month
-46.51%
-46.51%
6 Month
-55.77%
-55.77%
1 Year
-81.17%
-81.17%

More News

Read More
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Bionano Genomics's Earnings Outlook
Via Benzinga
The Latest Studies by Bionano Genomics Are Promising, But It’s Not a Buy Yet
Via InvestorPlace
Why Bionano Genomics Stock Is Risky, but a Good Bet
Via InvestorPlace
Hold On to Bionano Genomics Stock Until It Reaches $6 at Least
Via InvestorPlace
Earnings Scheduled For March 1, 2022
Via Benzinga
Bionano Genomics Stock Can Regain the Crucial $5 Level
Via InvestorPlace
Bionano Genomics May Finally Offer a Reward for Your Risk
Via InvestorPlace
Bionano Genomics's Return On Capital Employed Insights
Via Benzinga
Bionano Genomics's Earnings Outlook
Via Benzinga
Bionano Genomics Has Attractive Applications But An Unattractive Stock Price
Via InvestorPlace
Bionano Stock Looks to Have a Monster Comeback in Its Future
Via InvestorPlace
Investors Have Cast Their ‘No’ Votes Against Bionano Genomics
Via InvestorPlace
Bionano Is Not the Genomics Stock To Bet On
Via InvestorPlace
Bionano Genomics Is Interesting as Genome Testing Scales Upwards
Via InvestorPlace
Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations
Via Benzinga
7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now
Via InvestorPlace
Bionano Genomics Stock Is a Low-Priced Bet on Sound Science
Via InvestorPlace
The Critics Are Wrong About Bionano Stock
Via InvestorPlace
This Analyst’s Saphyr Calculations Suggest Buying Bionano While It’s Down
Via InvestorPlace
5 Penny Stocks Insiders Are Buying
Via Benzinga
Bionano Genomics Proves Not Everything Genetic is Gold
Via InvestorPlace
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.